戴氏虫草多糖及其应用

By preparing and applying Cordyceps militaris polysaccharide to regulate intestinal flora and protect the intestinal barrier, the problem of inflammatory damage to pancreatic β cells in T1DM was solved, achieving the effects of lowering blood glucose, increasing the number of pancreatic β cells and improving intestinal barrier function, thus providing a new therapeutic drug option for T1DM.

CN117924533BActive Publication Date: 2026-07-17AFFILIATED HOSPITAL OF ZUNYI UNIV

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
AFFILIATED HOSPITAL OF ZUNYI UNIV
Filing Date
2024-01-26
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Currently, there are no effective drugs for treating type 1 diabetes mellitus (T1DM), especially immunomodulatory drugs that cannot protect pancreatic β cells from inflammatory damage and have few side effects, and the role of the existing gut microbiota in the pathogenesis of T1DM is not yet fully understood.

Method used

We provide Cordyceps militaris polysaccharides, which regulate intestinal flora and protect intestinal barrier function. The specific methods include water bath extraction, anhydrous ethanol precipitation and purification. Cordyceps militaris polysaccharides obtained by these methods regulate intestinal flora structure, inhibit the expression of inflammatory factors, promote the production of short-chain fatty acids, and increase the expression of colonic tight junction proteins.

Benefits of technology

Cordyceps militaris polysaccharides can reduce the abundance of cyanobacteria and molluscs, increase the abundance of Cordyceps, Corynebacterium and Flavobacterium, inhibit the abundance of Escherichia and Salmonella, inhibit the expression of inflammatory factors in the colon and serum, promote the production of short-chain fatty acids, improve intestinal barrier damage, reduce blood glucose levels in diabetic mice, increase the number of pancreatic β cells and reduce their apoptosis, regulate the structure of intestinal flora, and provide a new drug option for the treatment of T1DM.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117924533B_ABST
    Figure CN117924533B_ABST
Patent Text Reader

Abstract

本方案公开了生物医药技术领域的一种戴氏虫草多糖,以及其在制备调节肠道菌群、改善肠道屏障功能的药物或保健品中的应用。本发明将戴氏虫草的主要活性成分—戴氏虫草多糖,应用于调节肠道菌群、改善肠道屏障功能中。通过实验首次证明戴氏虫草多糖能够调节链脲佐菌素诱导的糖尿病小鼠肠道菌群结构和丰度,包括上调罗氏菌属(Roseburia)、厌氧棒杆菌(Anaerostipes)和黄杆菌属(Flavonifractor)等有益菌的丰度,降低结肠和血清炎症因子表达,增加结肠内容物中短链脂肪酸如丙酸和丁酸等的含量,上调肠道紧密连接蛋白表达,从而起到改善肠道屏障功和降血糖作用。
Need to check novelty before this filing date? Find Prior Art